Heart Failure Society Of America, FDA Seek Consensus On Trial Endpoints
This article was originally published in The Gray Sheet
Executive Summary
Representatives of the Heart Failure Society of America and FDA likely will meet this fall to develop an HFSA position paper on heart failure device clinical trial endpoints, HFSA says
You may also be interested in...
Heart Failure Device Trial Investigators Search For Metrics Beyond Mortality
FDA should collaborate with the Heart Failure Society of America to draft guidelines for composite and surrogate endpoints in heart failure device trials, HFSA workshop participants urged April 1
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.